Novo Nordisk A/S had a pretty good 2023, its full-year sales increasing by 36% at constant exchange rates and its operating profit by 44% – both above analysts’ expectations. It achieved its goal of securing more than a third of the entire global diabetes market, and thanks to the relaunch of Wegovy (semaglutide injection) a year or so ago, saw its obesity sales jump by 154% globally and nearly 400% in the US.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?